[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632924":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":43,"centralContacts":47,"locations":11,"responsibleParty":53,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":11,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":86,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":11},{"fullName":5,"class":6},"Nurix Therapeutics, Inc.","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"NX-5948 + venetoclax","EXPERIMENTAL",null,[13,14],"Drug: NX-5948","Drug: venetoclax",{"label":16,"type":10,"description":11,"interventionNames":17},"NX-5948 + venetoclax + rituximab",[13,14,18],"Drug: rituximab",{"label":20,"type":10,"description":11,"interventionNames":21},"NX-5948 + venetoclax + obinutuzumab",[13,14,22],"Drug: obinutuzumab",[24,31,35,39],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","NX-5948","Administered orally once daily as a capsule",[9,20,16],[30],"bexobrutideg",{"type":25,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"venetoclax","Administered orally once daily as a tablet per prescribing information",[9,20,16],{"type":25,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"rituximab","Administered as an intravenous (IV) infusion per prescribing information",[16],{"type":25,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"obinutuzumab","Administered as an IV infusion per prescribing information",[20],[44],{"name":45,"affiliation":5,"role":46},"Study Director","STUDY_DIRECTOR",[48],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},"Additional Site Contact Information","CONTACT","415-417-3418","clinicaltrials@nurixtx.com",{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100632924","phase-1-study-of-nx-5948-in-combination-with-other-agents-in-adults-with-b-cell-malignancies-100632924",false,"NCT07520006","Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","An Open-label, Multicenter Phase 1b\u002F2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate organ and bone marrow function\n* Measurable disease by computed tomography (CT) per iwCLL\n* For R\u002FR CLL\u002FSLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)\n* For 1L CLL\u002FSLL, confirmed previously untreated CLL\u002FSLL with a clinical indication for systemic treatment that meets iwCLL criteria\n* Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate\n\nKey Exclusion Criteria:\n\n* Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment\n* Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment\n* Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation\n* Use of systemic corticosteroids (\\>20 mg\u002Fday prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast\n* Previously treated with a BTK degrader\n* Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment\n* Known central nervous system (CNS) lymphoma or leukemia\n* Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment\n* Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment\n\nNote: Other Inclusion\u002FExclusion criteria may apply as defined in the protocol.","ALL","18 Years",{"count":65,"type":66},150,"ESTIMATED","INTERVENTIONAL",[69,70],"PHASE1","PHASE2","The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed\u002Frefractory (R\u002FR) or first-line (1L) chronic lymphocytic leukemia (CLL)\u002Fsmall lymphocytic lymphoma (SLL).",[73,74,75],"B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[77,78,79,80,81,82,83,84,85],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)","Degrader","B-cell malignancy","BTKi","Bexobrutideg","Venetoclax","Obinutuzumab","Rituximab","NOT_YET_RECRUITING","2026-04-08",{"date":89,"type":90},"2026-04-13","ACTUAL",{"date":92,"type":66},"2026-05",{"date":94,"type":66},"2033-05",{"name":5,"class":6}]